A very recent publication of Clement et al. has recommended that couples with a long history of infertility should be analysed for Methylenetetrahydrofolate Reductase (MTHFR) polymorphism and homocysteine.
The group tested blood homocysteine (Hcy) level before and after treatment with Quatrefolic®to control the efficacy of the treatment before starting Assisted Reproductive Technology (ART) attempts.
In the 89 couples included – 50 were heterozygous for the MTHFR polymorphism, 39 homozygous – Quatrefolic® reduced rapidly the Hcy level of 42.7% in homozygous and 20.1% in heterozygous subjects, with no significant difference (p = 0.12) between the normalized Hcy level of homozygous and heterozygous (10.5 mmol/L vs. 9.8 mmol/L).
Reference: Clément A, Menezo Y, Cohen M, Cornet D, Clément P. 5-Methyltetrahydrofolate reduces blood homocysteine level significantly in C677T methyltetrahydrofolate reductase single-nucleotide polymorphism carriers consulting for infertility. J Gynecol Obstet Hum Reprod. 2020
The positive effect of Quatrefolic® (400 µg plus B6 and B12) in lowering and normalizing homocysteine has been also evaluated versus conventional supplementation of high dose of folic acid (5 mg/day) in hypertensive subjects at low cardiovascular risk. Quatrefolic® treatment was more effective in reducing homocysteine serum level than folic acid, normalizing homocysteine in 55.8% of cases, significantly higher than in the control one.
Reference: Mazza A, Cicero AF, Ramazzina E, Lenti S, Schiavon L, Casiglia E, Gussoni G. Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial. J Biol Regul Homeost Agents. 2016.